Τόμος 23 (2009) – Τεύχος 2 – Άρθρο 1 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 23 (2009) – Issue 2 – Article 1 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Title Hepatitis C: epidemiologic investigation and therapeutical treatment in Greece
Authors Marianna Diomidous1, Stelios Zimeras2, Dimitris Zikos1, Dimitris Charalabidesand Ioannis Pistolis1

1. Department of Public Health, Faculty of Nursing, University of Athens, Athens, Hellas

2. Department of Statistics and Actuarial Financial Mathematics, University of the Aegean, Samos, Hellas

3. MD Saint Olga Hospital, N. Ionia, Athens, Hellas

Citation Diomidous, M., Zimeras, S., Zikos, D., Charalabides, D., Pistolis, I.: Hepatitis C: epidemiologic investigation and therapeutical treatment in Greece, Epitheorese Klin. Farmakol. Farmakokinet. 23(2): 51-57 (2009)
Publication Date Accepted for publication (Final version): July 1, 2009
Full Text Language English
Order – Buy  Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)

pharmakonpress[at]pharmakonpress[.]gr

Keywords Hepatitis C, interferon a, PCR, logistic regression, non-parametric test.
Other Terms review article
Summary The CV infection is a serious public health problem and according to WHO and CDC more than 500.000 individuals have been infected worldwide, from which the 85% have developed chronic hepatitis C. Despite the fact that hepatitis C causes diffuse necrosis and liver inflammation, the therapeutic approach of the disease with a combined interferon and ribavirin treatment, has improved survival rates. The aim of the present study is to analyze a sample of 265 patients with hepatitis C from the Hepatologic Centre of the ‘Elena’ hospital in Athens, Greece and to investigate potential virologic, clinical and demographic characteristics of the patients that may constitute important correlation factors. Advanced statistical techniques have been applied to investigate the significant factors that affect PCR values. Application of x2-test indicates that a significant difference was found between: PCR values vs SGPT (Fisher test, p=0.0001). With the use of factor analysis, a model has been implemented, including two factors which interpret the 74.35% of the initial information. Finally, a predictive logistic regression model has been used for the PCR and SGPT factors, predicting 92.4% of the corrected values of PCR.
References 1.      Proceeding of the international Workshop on Epidemiology: Diagnosis and management of Hepatitis C infection. Med. Comm. 6-7: 1-32 (1996)

2. World Health Organization: Hepatitis C. Weekly Epidemiological Report 72: 65-69 (1997)

3. World Health Organization: Hepatitis C. Available from http://www.who.int/inf-fs/en/fact164.html

4. Viral Hepatitis Prevention Board: Hepatitis A, B and C: Defining Workers at Risk. Viral Hepatitis: 3, 1995

5. Houghton M.: Hepatitis C viruses. In: (Fields B., Knipe D., Howley P., eds) Fields Virology. Third edition. Pp. 1035-1058, Lippincott-Raven, Philadelphia, 1996

6. Purcell R.: Hepatitis C Virus. In: (Webster R., Granoff A., eds) Encyclopedia of Virology. Pp. 569-574, Academic Press Ltd, London, 1994

7. Hsu H., Greenberg H.: Hepatitis C. In: (Hoeprich P., Jordan M., Ronald A., eds) Infectious Diseases. A treatise of infectious processes. 5th ed., Pp.820-825, JB Lippincott Co, Philadelphia, 1994

8. Lemon S., Brown E.: Hepatitis C Virus. In: (Mandell G., Bennett J., Dollin R., eds) Principle and Practice of Infectious Disease, Fourth Edition, pp. 1474-1486, Churchill Livingston New York, 1995

9. Urdea M., Wuestehube L., Laurenson P., Wilber J.: Hepatitis C: diagnosis and monitoring. Clin. Chem. 43(8 Pt2): 1507-1511 (1997)

10. Naoumov N.: Hepatitis C virus infection in Eastern Europe. J. Hepatol. 31(Suppl 1): 84-87 (1999)

11. Papadimitropoulos B., Goustozi A., Papaioannou Ch. Et al.: Prevalence of the HCV infection in the general population of different Greek regions in: (Xatzigiannis S., ed) Hepatitis C. Pp. 163-170, Medical Publications Paschalidis, Athens, 1998

12. Davis G.: The challenge of progressive hepatitis C following liver transplantation. Liver Transpl. 9: 331 (2003)

13. Ntourakis D.: HCV virus. Arch. Hel. Med. 11(Suppl. A): A43-A84 (1994)

14. Trepo C., Pradat P.: Hepatits C Virus Infection in Western Europe. J. Hepatol. 31(Suppl. 1):80-83 (1999)

15. Van der Poel C.: Hepatitis C virus and blood transfusion: past and present risks. J. Hepatol. 31(suppl. 1): 101-106 (1999)

16. Dienstag J.L.: Sexual and perinatal transmission of hepatitis C. J. Hepatol. 26(Suppl. 1): 665-705 (1997)

17. Zanetti A.R., Tanzi E., Newell M.L.: Mother to infant transmission of Hepatitis C. J. Hepatol. 31(Suppl. 1): 96-100 (1999)

18. European Monitoring Centre for Drugs and Drug Addiction: Annual Report 2006. Available from: http://ar2006.emcdda.europa.eu/download/ar2006-en.pdf

19. Reichard O., Norkrans G., Fryden A., Braconier J.-H., Sonnerborg A., Weiland O.: Randomised, double-blind, placebo-controlled trial of interferon-alpha-2B with and without ribavirin for chronic hepatitis C. Lancet 351: 83-87 (1998)

20. National Institutes of Health Consensus Conference statement. Hepatology 36: S3 (2002)

21. Melzak R., Torgerson W.: On the language of pain. Anaesthesiology 34: 50-59 (1971)

22. Hadziyannis S.J., Papatheodoridis G.V., Dimou E., Laras A., Papaioannou C.: Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32: 847-851 (2000)

23. American Gastroenterological Association. Technical Review on the Management of Hepatitis C. Gastro. 130: 231 (2006)

24. Kim W., Brown R.S.,Jr, Tarrault N.A., El-Sergag H.: Burden of liver disease in the United States: summary of a workshop. Hepatology 36: 227-242 (2002)

25. Foster G.R.: Hepatitis C virus infection: quality of life and side effects of treatment. J. Hepatol. 31(suppl. 1): 250-254 (1999)

26. Spiegel B., Younossi Z., Hays R., Reviski D., Robbins S., Kanwall F.: Impact of hepatitis C on health related quality of life: A systematic review ad quantitative assessment. Hepatology 41: 790-800 (2005)

27. Feste C., Anderson R.: Empowerment: From philosophy to practice. Patient Educ. Couns. 26(1-3): 139-144 (1995)

28. Kontorinis N., Garas G., Young J., Speers D., Chester B., MacQuillan G., et al.: Outcome, tolerability and compliance of compassionate use interferon and ribavirin for Hepatitis C interferon in a shared care hospital clinic. Intern. Med. J. 33: 500-504 (2003)

29. Ruland C., Bakken S.: Development, implementing and evaluation of decision support systems for shared decision making in patient care: A conceptual model and case illustration. J. Biomed. Inform. 35(5-6): 313-321 (2002)

Relative Papers

Online ISSN 1011-6575

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:

Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor

Τι είναι η Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση-Οδηγίες προς τους Συγγραφείς – 
What is Epitheorese Klinikes Farmakologias 
και Farmakokinetikes-International Edition-Instrunctions to Authors

Άρθρα Δημοσιευμένα στην Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – 
Articles Published in Epitheorese Klinikes Farmakologias 
και Farmakokinetikes-International Edition

Συντακτικη Επιτροπή-Editorial Board

ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2009 – ANNUAL SUBSCRIPTION 2009
Γλώσσα Πλήρους Κειμένου – Full Text Language Αγγλικά – English
Παραγγελία – Αγορά – Order – Buy Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)

pharmakonpress[at]pharmakonpress[.]gr

Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)

pharmakonpress[at]pharmakonpress[.]gr

 

 

 

 

Bookmark the permalink.

Comments are closed.